Atryn Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Atryn market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to the rising demand for antithrombin products, the increasing prevalence of thromboembolic disorders, higher rates of hereditary antithrombin deficiency, growing awareness of rare diseases, and the expansion of healthcare infrastructure.

Growth during the market's forecast period can be driven by the expanding use of antithrombin products, the rising incidence of coagulation disorders, an increase in chronic conditions, a higher number of surgical procedures, and the growing adoption of diagnostic kits. Key trends in the forecast period include advancements in production methods, increased research and development, the introduction of innovative manufacturing techniques, the rise of combination therapies, and global health initiatives.

The growing prevalence of chronic conditions is expected to drive the growth of the atryn market in the future. Chronic conditions are long-term health issues that usually require ongoing management or treatment. The rise in chronic conditions is linked to factors such as an aging population, unhealthy lifestyles, and improved access to healthcare. Atryn, a recombinant antithrombin therapy, helps patients with chronic conditions by preventing harmful blood clots, thus reducing the risk of severe complications and enhancing long-term health outcomes. For example, a report published in April 2022 by the National Association of Chronic Disease Directors (NACDD) stated that nearly 60% of adult Americans have at least one chronic disease, and around 40% of adults have multiple chronic conditions (MCC), which is expected to cost the U.S. economy $2 trillion annually by 2030, or $8,600 per person. As such, the rise in chronic conditions will significantly boost the atryn market.

The increasing emphasis on personalized medicine is anticipated to fuel the growth of the atryn market. Personalized medicine tailors medical treatments to an individual’s unique genetic profile, environment, and lifestyle for optimal effectiveness. This growing focus on personalized medicine stems from its potential to improve treatment outcomes, reduce side effects, optimize resource use, and meet the increasing demand for tailored healthcare. Atryn plays a key role in personalized medicine by offering targeted treatment for patients with specific antithrombin deficiencies, ensuring safer and more effective prevention of life-threatening clotting disorders during critical medical procedures. For instance, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of the atryn market.

A key trend in the atryn market is the development of contract development and manufacturing organizations (CDMOs) specializing in the production of therapeutic proteins, primarily using cell culture techniques. A CDMO is a company that offers comprehensive services to the pharmaceutical, biotechnology, and medical device industries. For example, in October 2023, LFB Biomanufacturing, a biotechnology company based in France, launched an initiative to increase its bioproduction capacity at the Alès site with support from the "France 2030" plan. This expansion aims to enhance the production of innovative therapies, especially those derived from cell culture, and represents a strategic effort by LFB to significantly boost its ability to manufacture therapeutic proteins and biological drugs in France, advancing treatments for rare diseases and strengthening the country's biomanufacturing sector.

The key company operating in the atryn market is rEVO Biologics Inc.

North America was the largest region in the atryn market in 2024. The regions covered in atryn report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the atryn market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Atryn is a recombinant human antithrombin protein produced using genetically modified goats. It is primarily used to prevent blood clots in patients with hereditary antithrombin deficiency, especially in high-risk situations such as surgery or childbirth.

The main methods of administration in the atryn market are intravenous (IV) and subcutaneous (SC) injections. IV administration involves delivering medication directly into a vein through an intravenous line, allowing for immediate absorption and precise control over dosage, making it ideal for emergencies or cases requiring rapid therapeutic intervention. The distribution channels for Atryn include direct sales, retail pharmacies, and online pharmacies. Its various applications address conditions such as hereditary antithrombin deficiency, acquired antithrombin deficiency, and others, with end-users including hospitals, specialized clinics, and home care settings.

The atryn market research report is one of a series of new reports that provides atryn market statistics, including atryn industry global market size, regional shares, competitors with a atryn market share, detailed atryn market segments, market trends and opportunities, and any further data you may need to thrive in the atryn industry. This atryn market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atryn market includes revenues earned by entities by recombinant human antithrombin, biologic drug formulations, and active pharmaceutical ingredients (APIs). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.